Please assess the completion status of the following clinical trial:

Trial Title: The Effects of the Dietary Supplement CardioFlex Q10 on Reducing Cardiovascular Disease Risk Factors in Adults

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: TRIPLE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Age 30-65~* An accelerated plethysmograph (APG) type (biological age of arteries) of D, E, F or G and/or a high density lipoprotein (HDL) to total cholesterol (TC) ratio of ≤24 percent~Exclusion Criteria:~* Have used prescription cholesterol or blood pressure medication in the last 3 months~* Perform more then 150 minutes of moderate to rigorous activity per week~* Pregnant or planning on getting pregnant during the study period

- Gender: ALL
- Minimum Age: 30 Years
- Maximum Age: 65 Years
- Healthy Volunteers: t

Study Arms:
- Experimental group (Type: EXPERIMENTAL): Participants in the experimental group will be given 1 serving (10g) of Cardioflex each day.
- Control Group (Type: PLACEBO_COMPARATOR): Participants in the control group will be given a flavoured 10g placebo that looks and tastes exactly like Cardioflex.

Based on this trial design, predict the completion outcome and termination type (if applicable).